As of 2025-07-19, the EV/EBITDA ratio of Hyloris Pharmaceuticals SA (HYL.BR) is -30.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HYL.BR's latest enterprise value is 167.87 mil EUR. HYL.BR's TTM EBITDA according to its financial statements is -5.43 mil EUR. Dividing these 2 quantities gives us the above HYL.BR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.3x - 18.3x | 13.4x |
| Forward P/E multiples | 6.7x - 9.4x | 8.0x |
| Fair Price | (0.64) - (1.06) | (1.32) |
| Upside | -109.5% - -115.6% | -119.5% |
| Date | EV/EBITDA |
| 2025-07-16 | -29.07 |
| 2025-07-15 | -28.14 |
| 2025-07-14 | -28.55 |
| 2025-07-11 | -28.35 |
| 2025-07-10 | -28.97 |
| 2025-07-09 | -28.04 |
| 2025-07-08 | -27.73 |
| 2025-07-07 | -28.45 |
| 2025-07-04 | -28.45 |
| 2025-07-03 | -28.35 |
| 2025-07-02 | -28.55 |
| 2025-07-01 | -28.35 |
| 2025-06-30 | -29.07 |
| 2025-06-27 | -28.04 |
| 2025-06-26 | -28.55 |
| 2025-06-25 | -28.45 |
| 2025-06-24 | -28.35 |
| 2025-06-23 | -26.59 |
| 2025-06-20 | -26.28 |
| 2025-06-19 | -26.39 |
| 2025-06-18 | -26.28 |
| 2025-06-17 | -26.49 |
| 2025-06-16 | -26.49 |
| 2025-06-13 | -25.97 |
| 2025-06-12 | -26.59 |
| 2025-06-11 | -27.01 |
| 2025-06-10 | -27.01 |
| 2025-06-09 | -27.42 |
| 2025-06-06 | -27.63 |
| 2025-06-05 | -28.35 |
| 2025-06-04 | -27.93 |
| 2025-06-03 | -26.70 |
| 2025-06-02 | -27.32 |
| 2025-05-30 | -26.49 |
| 2025-05-29 | -25.77 |
| 2025-05-28 | -25.36 |
| 2025-05-27 | -25.77 |
| 2025-05-26 | -26.49 |
| 2025-05-23 | -26.49 |
| 2025-05-22 | -26.90 |
| 2025-05-21 | -25.36 |
| 2025-05-20 | -25.77 |
| 2025-05-19 | -26.08 |
| 2025-05-16 | -26.18 |
| 2025-05-15 | -27.32 |
| 2025-05-14 | -27.01 |
| 2025-05-13 | -25.97 |
| 2025-05-12 | -24.94 |
| 2025-05-09 | -25.51 |
| 2025-05-08 | -25.98 |